stockrowAditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024.
- Revenue
- +1,120.0%
- EPS
- +99.6%
- Free cash flow
- +60.8%
Quarter to March 2026, against a year earlier
Follow ADTX
Alert me
Aditxt, Inc. (ADTX) Altman Z-score
Aditxt, Inc.'s Altman Z-score for fiscal 2025 is −22.29, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −22.29 | (11.33) |
| FY2024 | −10.96 | (6.21) |
| FY2023 | −4.75 | (1,419,024.68) |
| FY2022 | 1419019.93 | (3,204,595.14) |
| FY2021 | 4623615.07 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.51) | — | −0.61 | |
| Retained earnings / total assets | (12.70) | — | −17.78 | |
| EBIT / total assets | (1.18) | — | −3.91 | |
| Market value of equity / total liabilities | 0.02 | — | 0.01 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −22.29 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −52.38 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| OSRH OSR Health, Inc. compare | −0.6× |
| CELZ Creative Medical Technology Holdings, Inc. compare | −4.3× |
| NIKI Niki BioSolutions, Inc. compare | −5.0× |
| AZTR Azitra, Inc. compare | −14.7× |
| ADTX Aditxt, Inc. | −22.3× |
| XBIO Xenetic Biosciences, Inc. compare | −30.9× |
| NCNA NuCana PLC Sponsored ADR compare | — |
| PMCB Nuvilex Inc. compare | — |
| SKYE Skye Bioscience, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets